ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company.
Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
ITM Isotopen Technologien München AG was founded in 2004 and is the holding company for its subsidiaries ITG Isotopes Technologies Garching GmbH, ITM P4 Diagnostics GmbH and ITM Oncologics GmbH. ITM is privately held and responsible for the management and administration of its wholly owned subsidiaries, together with the administration of IP.
Since 2007 the name ITG Isotopes Technologies Garching GmbH has stood for the highest level of quality and reliability in the sourcing, processing, radiolabeling and sales of radionuclides and for the marketing of devices. ITG´s unrivaled logistics network allows guaranteed shipment within 24-48 hrs (Europe) and 72 hrs (Overseas) respectively.
ITM Oncologics develops innovative product candidates in the field of Targeted Radionuclide Therapy in Precision Oncology. It aims to identify, either independently or in collaboration with partners, appropriate targets and targeting molecules, and to link these with radionuclides for cancer therapy. ITM Oncologics has a number of very interesting candidates in the early clinical or pre-clinical phase, for example in the field of bone metastasis. Our lead product Solucin® is currently undergoing a phase III clinical trial, known as COMPETE. COMPETE is an international pivotal multi-center phase III clinical trial evaluating the efficacy and safety of n.c.a.177Lu-Edotreotide (Solucin®) compared to Everolimus in patients with inoperable, progressive, somatostatin-receptor positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET).
The subsidiary ITM P4 Diagnostics connects ITM Oncologics with the development of next generation precision diagnostics based on a proprietary biomolecule portfolio and the genetic fingerprints of targeted tumors.